Insider Selling: Verve Therapeutics, Inc. (NASDAQ:VERV) CFO Sells 3,350 Shares of Stock

Verve Therapeutics, Inc. (NASDAQ:VERV) CFO Allison Dorval sold 3,350 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total value of $13,902.50. Following the completion of the transaction, the chief financial officer now directly owns 13,280 shares of the company’s stock, valued at $55,112. The trade was a 20.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Verve Therapeutics Stock Performance

NASDAQ:VERV opened at $3.62 on Friday. The stock has a market capitalization of $321.44 million, a PE ratio of -1.47 and a beta of 1.77. Verve Therapeutics, Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $9.31. The company has a fifty day moving average of $6.61 and a two-hundred day moving average of $6.02.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Research analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VERV shares. Royal Bank of Canada decreased their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research report on Tuesday, March 25th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Guggenheim reaffirmed a “buy” rating on shares of Verve Therapeutics in a report on Tuesday, March 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $20.67.

Hedge Funds Weigh In On Verve Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC acquired a new position in Verve Therapeutics in the 3rd quarter valued at $165,000. Charles Schwab Investment Management Inc. raised its position in shares of Verve Therapeutics by 28.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after buying an additional 126,110 shares during the last quarter. FMR LLC lifted its stake in shares of Verve Therapeutics by 0.3% in the third quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after buying an additional 3,873 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Verve Therapeutics by 6.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,041 shares of the company’s stock worth $557,000 after acquiring an additional 6,595 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in Verve Therapeutics during the 3rd quarter valued at about $139,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.